# SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

> **NCT04762160** · PHASE2 · TERMINATED · sponsor: **Epizyme, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Tazemetostat
- **COMBINATION_PRODUCT:** Rituximab

## Key facts

- **NCT ID:** NCT04762160
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-15
- **Primary completion:** 2022-03-22
- **Final completion:** 2022-03-22
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Decision to terminate EZH-1401 was solely due to company business decision.
- **Last updated:** 2024-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762160, "SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04762160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*